Shared and unique effects of ApoEε4 and pathogenic gene mutation on cognition and imaging in preclinical familial Alzheimer’s disease

Table 1 Subject demographic and clinical data

	Control^a (n = 76)	*APOE*ε4 (n = 26)	*APP* (n = 17)	*PS1* (n = 20)	P-value
Age (years)	44.37 (12.69)	44.54 (12.76)	35.65 (15.39)	33.95 (14.66)*	0.003**
Sex (male/female)	25/51	12/14	5/12	8/12	> 0.05
Education (years)	10.74 (5.48)	11.77 (4.68)	14.41 (2.27)*	10.25 (4.52)	0.034*
EYO (years)^b	− 14.47 (11.08)	− 16.08 (9.77)	− 13.18 (13.73)	− 11.07 (13.38)	> 0.05
MMSE^c	29.06 (0.18)	28.96 (0.30)	28.41 (0.37)	28.88 (0.35)	> 0.05
MoCA^d	27.07 (2.26)	27.29 (2.53)	28.29 (1.57)	26.35 (3.56)	> 0.05
Subject numbers
T1 MRI after PP^e	70	24	17	20
DTI after QC^f + PP	33	12	9	13
rsfMRI after QC + PP	65	17	11	16

For continuous variables, data are shown in mean (SD) and one-way ANOVA with post hoc between-group comparisons using Bonferroni analysis; for categorical variables, chi-square test was used to compare between groups (APOEε4 vs. control, APP vs. control, PS1 vs. control). *0.01 < P < 0.05, **0.001 < P < 0.01
^aControl: cognitive normal subjects not carrying APOEε4 or known pathogenic gene mutation
^bEYO: estimated years from symptom onset
^cMMSE = Mini-Mental State Examination
^dMoCA = Montreal Cognitive Assessment
^ePP: pre-processing
^fQC: quality control

ISSN: 1758-9193